Aktienkurs
83,44
$
-6,89
7,63 %1 M.
+5,08
6,48 %6 M.
-5,92
6,62 %YTD
+4,82
6,13 %1 J.
+15,13
22,15 %3 J.
-9,27
10,00 %5 J.
+43,24
107,56 %10 J.
Nasdaq,
Schlusskurs Di, 27.09.2022
Powered by
ISIN
US09061G1013
Symbol
BMRN
Index
Sektor
Industrie
Kennzahlen
BETA
BETA
| Marktkapitalisierung | 15,48 Mrd. USD |
| Enterprise Value | 15,45 Mrd. USD |
| KGV (TTM) KGV | 330,06 |
| EV/FCF (TTM) EV/FCF | 990,84 |
| EV/Sales (TTM) EV/Sales | 8,15 |
| KUV (TTM) KUV | 8,17 |
| KBV (TTM) KBV | 3,44 |
| Umsatzwachstum (TTM) Umsatzwachstum | -1,25 % |
| Umsatz (TTM) Umsatz | 1,89 Mrd. USD |
Mehr anzeigen
Finanzdaten von Biomarin Pharmaceutical
| Jun. '22 |
+/-
%
|
||
| Umsatz | 1.895 1.895 |
1 %
1 %
|
|
| Bruttoertrag | 1.369 1.369 |
6 %
6 %
|
|
| EBITDA | 42 42 |
33 %
33 %
|
EBIT (Operatives Ergebnis) EBIT | -64 -64 |
28 %
28 %
|
| Nettogewinn | 54 54 |
94 %
94 %
|
|
Angaben in Millionen USD.
Biomarin Pharmaceutical Aktie News
The Motley Fool
6 Tage alt
|
Positiv
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
PRNewsWire
13 Tage alt
|
Neutral
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report
Institute for Clinical and Economic Review (ICER) Base-Case Model Report Results in $4 Million Savings Versus Emicizumab Prophylaxis Per Patient Over a Lifetime Biologics License Application (BLA) Resubmission to FDA on Track for End of September 2022 SAN RAFAEL, Calif. , Sept. 15, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Institute for Clinical a...
Institute for Clinical and Economic Review (ICER) Base-Case Model Report Results in $4 Million Savings Versus Emicizumab Prophylaxis Per Patient Over a Lifetime Biologics License Application (BLA) Resubmission to FDA on Track for End of September 2022 SAN RAFAEL, Calif. , Sept. 15, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Institute for Clinical a...
PRNewsWire
etwa ein Monat alt
|
Neutral
First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)
Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA Determination of ODD Conference Call and Webcast to be Held Wed., Aug. 24th at 8:00 pm Eastern SAN RAFAEL, Calif.
Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA Determination of ODD Conference Call and Webcast to be Held Wed., Aug. 24th at 8:00 pm Eastern SAN RAFAEL, Calif.
Firmenprofil
BioMarin Pharmaceutical, Inc. ist ein Biotechnologieunternehmen, das sich mit der Entwicklung und Kommerzialisierung von Therapien für Menschen mit schweren und lebensbedrohlichen seltenen Krankheiten und Beschwerden beschäftigt. Zu seiner Pipeline gehören Vosoritide (BMN 111) für Achondroplasie und das Valoctocogene Roxaparvovec (BMN 270) für Hämophilie A. Das Unternehmen wurde am 21. März 1997 von John C. Klock, Christopher M. Starr und Grant W. Denison gegründet und hat seinen Hauptsitz in San Rafael, Kalifornien.
| Hauptsitz | USA |
| CEO | Jean-Jacques Bienaimé |
| Mitarbeiter | 3.045 |
| Gegründet | 1997 |
| Webseite | www.biomarin.com |
aktien.guide Premium
Mit dem Premium Zugang erhältst Du sämtliche Funktionen von aktien.guide uneingeschränkt mit Realtime-Kursen für 6.908 weltweite Aktien - auf komplett werbefreien Seiten.
* bei jährlicher Zahlung